Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 5 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Multiple Myeloma 1 Melanoma, Cutaneous Malignant 1 Lymphoma 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Glioblastoma 1 Gastroesophageal Cancer 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 19 Bevacizumab 14 Carboplatin 11 Standard of Care 10 Cyclophosphamide 9 Nivolumab 8 Cetuximab 8 Exercise 7 Doxorubicin 7 atezolizumab 6 Temozolomide 6 Radiotherapy 6 Pemetrexed 6 Paclitaxel 6 Blood Specimen Collection 6 durvalumab 5 Rituximab 5 Prednisone 5 Fluorouracil 5 Cisplatin 5 olaparib 4 dostarlimab 4 abemaciclib 4 Leucovorin 4 Gemcitabine 4 130-nm albumin-bound paclitaxel 4 venetoclax 3 temsirolimus 3 talazoparib 3 pertuzumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × relatlimab × 30 days × Clear all

NCT03899155 2026-05-27

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡